TITLE

Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor—Based versus Nonnucleoside Reverse-Transcriptase Inhibitor—Based Therapy

AUTHOR(S)
Goicoechea, Miguel; Shanshan Liu; Best, Brookie; Sun, Shelly; Jain, Sonia; Kemper, Carol; Witt, Mallory; Diamond, Catherine; Haubrich, Richard; Louie, Stan
PUB. DATE
January 2008
SOURCE
Journal of Infectious Diseases;1/1/2008, Vol. 197 Issue 1, p102
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Plasma concentrations of tenofovir increase when the drug is coadministered with some ritonavir-boosted protease inhibitors (PI/r). We hypothesized that tenofovir disoproxil fumarate (TDF)-treated patients taking PI/r-based regimens would have a greater decline in renal function than patients receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy. Methods. We compared the estimated decline in renal function among 146 human immunodeficiency virus type 1 (HIV-1)-infected patients receiving a TDF+PI/r- (n = 51), TDF+NNRTI- (n = 29), or non-TDF-containing (n = 66) regimen. Plasma tenofovir concentrations were measured at study week 2, and rates of creatinine clearance (CrCl) were estimated using the Cockcroft-Gault (C-G) and Modification of Diet in Renal Disease (MDRD) equations. Mixed-effects models were used to analyze regimen type and tenofovir concentration as predictors of change in CrCl from baseline to weeks 24 and 48. Results. Decreases in C-G estimates of CrCl were not significantly different among the 3 groups during the first 24 weeks of therapy. However, in adjusted analyses, patients receiving TDF+PI/r had a greater rate of decline in CrCl than did the TDF+NNRTI group (for C-G, -13.9 vs. -6.2 mL/min/year [P = .03]; for MDRD, -14.7 vs. -4.5 mL/min/1.73 m2/year [P = .02]). Among TDF-treated patients, tenofovir plasma concentration was not associated with CrCl over time. Conclusions. Treatment with TDF and PI/r was associated with greater declines in renal function over 48 weeks compared with TDF+NNRTI-based regimens.
ACCESSION #
29338308

 

Related Articles

  • HIV-1 reverse transcriptase inhibitors. Safadi, Yazan El; Vivet-Boudou, Valérie; Marquet, Roland // Applied Microbiology & Biotechnology;Jun2007, Vol. 75 Issue 4, p723 

    Reverse transcriptase (RT) is one of the three enzymes encoded by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of AIDS. Together with protease inhibitors, drugs inhibiting the RNA- and DNA-dependant DNA polymerase activity of RT are the major components of highly active...

  • Health Risks from HIV Drugs. SAMARAS, KATHERINE // Australasian Science;Jun2009, Vol. 30 Issue 5, p26 

    The article investigates the risks of anti-retroviral drugs despite their effectiveness in reducing the direct mortality rate of HIV. A combination of drugs from different classes is used by highly active anti-retroviral therapy (HAART), including protease inhibitors and nucleoside reverse...

  • HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation. Rhee, Soo-Yon; Liu, Tommy F.; Holmes, Susan P.; Shafer, Robert W. // PLoS Computational Biology;May2007, Vol. 3 Issue 5, pe87 

    Despite the high degree of HIV-1 protease and reverse transcriptase (RT) mutation in the setting of antiretroviral therapy, the spectrum of possible virus variants appears to be limited by patterns of amino acid covariation. We analyzed patterns of amino acid covariation in protease and RT...

  • Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Sharma, Prem L.; Nurpeisov, Viktoria; Hernandez-Santiago, Brenda; Beltran, Thierry; Schinazi, Raymond F. // Current Topics in Medicinal Chemistry;May2004, Vol. 4 Issue 9, p895 

    The development of novel compounds that can effectively inhibit both wild type and the most consensus resistant strains of human immunodeficiency virus type 1 (HIV-1) is the primary focus in HIV disease management. Combination therapy, comprising at least three classes of drugs, has become the...

  • Recognition and Management of Significant Drug Interactions in HIV Patients: Challenges in Using Available Data to Guide Therapy. Pau, A. K.; Boyd, S. D. // Clinical Pharmacology & Therapeutics;Nov2010, Vol. 88 Issue 5, p712 

    Combination antiretroviral therapy (cART) has improved survival rates in HIV-infected patients; however, patients now experience comorbidities that require pharmacological intervention, thereby increasing the risk of drug-drug interactions (DDIs). HIV protease inhibitors (PIs), non-nucleoside...

  • HIV integrase variability and genetic barrier in antiretroviral nave and experienced patients. Piralla, Antonio; Paolucci, Stefania; Gulminetti, Roberto; Comolli, Giuditta; Baldanti, Fausto // Virology Journal;2011, Vol. 8 Issue 1, p149 

    Background: HIV-1 integrase (IN) variability in treatment naïve patients with different HIV-1 subtypes is a major issue. In fact, the effect of previous exposure to antiretrovirals other than IN inhibitors (INI) on IN variability has not been satisfactorily defined. In addition, the genetic...

  • The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch, Khadija; Oulad-Lahcen, Ahd; Bensghir, Rajae; Blaghen, Mohamed; Elfilali, Kamal Marhoum; Ezzikouri, Sayeh; Abidi, Omar; Hassar, Mohamed; Wakrim, Lahcen // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p380 

    Background: The widespread use of antiretroviral agents and the growing occurrence of HIV-1 strains resistant to these drugs have given rise to serious concerns regarding the transmission of resistant viruses to newly infected persons, which may reduce the efficacy of a first-line antiretroviral...

  • Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis. Sungkanuparph, Somnuek; Overton, E. Turner; Seyfried, Warren; Groger, Richard K.; Fraser, Victoria J.; Powderly, William G. // Clinical Infectious Diseases;11/1/2005, Vol. 41 Issue 9, p1326 

    Background. Intermittent episodes of detectable human immunodeficiency virus (HIV) viremia (hereafter referred to as "blips") are generally not predictive of subsequent virologic failure. Limited data are available for patients treated with nonnucleoside reverse-transcriptase inhibitor...

  • Frecuencia de potenciales interacciones medicamentosas entre antirretrovirales y otros grupos farmacológicos en pacientes colombianos. Machado Alba, Jorge Enrique; Morales^Plaza, Cristhian David; Hoyos Soto, Valentina // Investigaciones ANDINA;abr-sep2014, Vol. 16 Issue 28, p910 

    Objectiv: determine the prevalence of potential risk drug interactions between antiretroviral and other drugs in Colombian patients with HIV/AIDS. Materials and methods: cross-sectional study who took the prescription drugs a population database of 6.2 million users from May 1 to July 31, 2012....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics